Product Information
RYBELSUS 14 MG TABLET is a brand product labeled by Novo Nordisk, priced at $33.1885 per EA under NDC 00169431430. Its NADAC has been published 237 times since Mar 23, 2022.
FDA first approved this application on Sep 20, 2019.
Strength
14 mg/1
Manufacturer
Novo NordiskNDC
00169431430
Classification
Brand
Dosage Form
TABLET
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
SEMAGLUTIDEApproval Type
New Drug (NDA)
FDA Application
NDA213051FDA Approved
9/20/2019
On Market Since
9/20/2019
Pharmacological Classes
Price Statistics
The NADAC for RYBELSUS 14 MG TABLET has been published 237 times since Mar 23, 2022, and over the history we have for it it has risen 16.0%. The table below summarizes its recorded NADAC range and movement.
| Current price | $33.1885 per EA |
|---|---|
| All-time high | $33.1885 (Sep 30, 2026) |
| All-time low | $28.5797 (Apr 20, 2022) |
| 52-week high | $33.1885 |
| 52-week low | $32.1894 |
| Median price | $31.1526 |
| Average price | $30.9922 |
| Largest weekly change | +4.9% (Jan 11, 2023) |
| Weeks tracked | 237 |
| Tracking since | Mar 23, 2022 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the Oral Semaglutide market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Novo Nordisk manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Oral Semaglutide market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
GLP-1 Receptor Agonist class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of RYBELSUS 14 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for RYBELSUS 14 MG TABLET, manufactured by Novo Nordisk, is $33.1885 per EA (NDC 00169431430), effective Sep 30, 2026.
How has the price of RYBELSUS 14 MG TABLET changed over time?
Over the history we have for it, the NADAC for RYBELSUS 14 MG TABLET has risen 16.0%. It has been tracked across 237 weekly CMS publications since Mar 23, 2022.
What are the highest and lowest recorded NADAC prices for RYBELSUS 14 MG TABLET?
Since Mar 23, 2022, the NADAC for RYBELSUS 14 MG TABLET has ranged from a low of $28.5797 (Apr 20, 2022) to a high of $33.1885 (Sep 30, 2026), with a median of $31.1526 per EA.
Are there cheaper alternatives to RYBELSUS 14 MG TABLET?
No other NADAC-published product currently shares the active ingredient and strength of RYBELSUS 14 MG TABLET in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures RYBELSUS 14 MG TABLET?
RYBELSUS 14 MG TABLET (NDC 00169431430) is labeled by Novo Nordisk, and CMS classifies it as a brand product.